{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:46:07Z","timestamp":1781311567894,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007263","name":"Astellas Foundation for Research on Metabolic Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009048","name":"Japanese Society of Clinical Neuropsychopharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010523","name":"Centre for Addiction and Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.schres.2019.09.013","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T18:38:24Z","timestamp":1574793504000},"page":"8-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms"],"prefix":"10.1016","volume":"215","author":[{"given":"Yutaro","family":"Shimomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2019.09.013_bib1","series-title":"Texas Medication Algorithm Project Procedual Manual Schizophrenia Treatment Algorithms","author":"Argo","year":"2008"},{"key":"10.1016\/j.schres.2019.09.013_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/08039488.2015.1074285","article-title":"Treatment of adult patients with schizophrenia and complex mental health needs \u2013 a national clinical guideline","volume":"70","author":"Baandrup","year":"2016","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.schres.2019.09.013_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2017.10.030","article-title":"Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis","volume":"195","author":"Bowtell","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.09.013_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2017.11.010","article-title":"Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review","volume":"197","author":"Bowtell","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.09.013_bib6","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jclinepi.2010.07.001","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"63","author":"Brouwers","year":"2010","journal-title":"J.\u00a0Clin. Epidemiol."},{"key":"10.1016\/j.schres.2019.09.013_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2019.09.013_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-015-0269-4","article-title":"The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics","volume":"29","author":"De Hert","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2019.09.013_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cpr.2013.04.001","article-title":"Assessing early signs of relapse in psychosis: review and future directions","volume":"33","author":"Eisner","year":"2013","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.schres.2019.09.013_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2013.05.016","article-title":"The evidence for illness progression after relapse in schizophrenia","volume":"148","author":"Emsley","year":"2013","journal-title":"Schizophr. Res."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.schres.2019.09.013_bib11","article-title":"The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders","volume":"64","author":"Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders","year":"2003","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.schres.2019.09.013_bib13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia","volume":"174","author":"Goff","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0019-5545.196973","article-title":"Clinical practice guidelines for management of schizophrenia","volume":"59","author":"Grover","year":"2017","journal-title":"Indian J. Psychiatr."},{"key":"10.1016\/j.schres.2019.09.013_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World federation of Societies of biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jpsychires.2012.02.013","article-title":"The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients","volume":"46","author":"Hori","year":"2012","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.schres.2019.09.013_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","article-title":"Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial","volume":"5","author":"Hui","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib18","series-title":"An Overview of Treatment of Schizophrenia with an Emphasis on Pharmacotherapy: Administration, Efficacy, and Side Effects","author":"International Psychopharmacology Algorithm Project","year":"2004"},{"key":"10.1016\/j.schres.2019.09.013_bib19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1017\/S0033291718001393","article-title":"Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: a meta-analysis","volume":"49","author":"Kishi","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2019.09.013_bib20","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1176\/appi.ajp.2010.09070937","article-title":"Processing speed deficits in schizophrenia: reexamining the evidence","volume":"167","author":"Knowles","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib21","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S1461145710001380","article-title":"Evidence-based pharmacotherapy of schizophrenia","volume":"14","author":"Leucht","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2019.09.013_bib23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2019.09.013_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/CIRCULATIONAHA.114.008779","article-title":"Association between antipsychotic use and risk of acute myocardial infarction","volume":"130","author":"Lin","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2019.09.013_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/appy.12234","article-title":"Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region","volume":"8","author":"Lo","year":"2016","journal-title":"Asia Pac. Psychiatr."},{"key":"10.1016\/j.schres.2019.09.013_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.schbul.a006926","article-title":"The Mount Sinai conference on the pharmacotherapy of schizophrenia","volume":"28","author":"Marder","year":"2002","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2019.09.013_bib27","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4088\/JCP.14m09540","article-title":"Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals","volume":"77","author":"Mayoral-van Son","year":"2016","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.schres.2019.09.013_bib29","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1017\/S0033291714000282","article-title":"Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study","volume":"44","author":"Morgan","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2019.09.013_bib30","series-title":"Psychosis and Schizophrenia in Adults: Treatment and Management","author":"National Collaborating Centre for Mental Health","year":"2014"},{"key":"10.1016\/j.schres.2019.09.013_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HRP.0b013e31827fd915","article-title":"The Psychopharmacology algorithm Project at the Harvard South Shore Program","volume":"21","author":"Osser","year":"2013","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0000000000001046","article-title":"Model-guided antipsychotic dose reduction in schizophrenia","volume":"39","author":"Ozawa","year":"2019","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2019.09.013_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study","volume":"341","author":"Parker","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2019.09.013_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.schres.2019.09.013_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.schres.2019.09.013_bib36","article-title":"Intermittent drug techniques for schizophrenia","volume":"CD006196","author":"Sampson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2019.09.013_bib37","author":"Scottish Intercollegiate Guidelines Network"},{"key":"10.1016\/j.schres.2019.09.013_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1017\/S109285291300014X","article-title":"\u201cMeta-guidelines\u201d for the management of patients with schizophrenia","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2019.09.013_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1192\/bjp.bp.116.186007","article-title":"One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis","volume":"211","author":"Takeuchi","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib40","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","article-title":"Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia","volume":"44","author":"Takeuchi","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2019.09.013_bib41","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/schbul\/sbt090","article-title":"Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study","volume":"39","author":"Takeuchi","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2019.09.013_bib42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jpsychires.2011.01.007","article-title":"How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review","volume":"45","author":"Takeuchi","year":"2011","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.schres.2019.09.013_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.schres.2011.11.021","article-title":"Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms","volume":"134","author":"Takeuchi","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.09.013_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0000000000000959","article-title":"Clinical characteristics of patients with schizophrenia who successfully discontinued antipsychotics","volume":"38","author":"Tani","year":"2018","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2019.09.013_bib45","series-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2018"},{"key":"10.1016\/j.schres.2019.09.013_bib46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1192\/bjo.2018.17","article-title":"Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review","volume":"4","author":"Thompson","year":"2018","journal-title":"BJPsych Open"},{"key":"10.1016\/j.schres.2019.09.013_bib47","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29\u202f823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","article-title":"20-Year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia","volume":"175","author":"Tiihonen","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2019.09.013_bib50","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects","volume":"31","author":"Uchida","year":"2011","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2019.09.013_bib51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamapsychiatry.2013.2993","article-title":"Early medication discontinuation on long-term recovery outcome in first-episode psychosis","volume":"71","author":"Undurraga","year":"2014","journal-title":"JAMA psychiatry"},{"issue":"521\u20135","key":"10.1016\/j.schres.2019.09.013_bib52","article-title":"Ministry of Health clinical practice guidelines: schizophrenia","volume":"52","author":"Verma","year":"2011","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.schres.2019.09.013_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41537-018-0056-6","article-title":"Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse","volume":"4","author":"Wang","year":"2018","journal-title":"NPJ Schizophr"},{"key":"10.1016\/j.schres.2019.09.013_bib54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2016.09.029","article-title":"Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis","volume":"179","author":"Winton-Brown","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.09.013_bib55","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 Years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2019.09.013_bib56","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/0269881118756062","article-title":"Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study","volume":"32","author":"Zhou","year":"2018","journal-title":"J.\u00a0Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419304232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419304232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:31:03Z","timestamp":1760297463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419304232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":56,"alternative-id":["S0920996419304232"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.09.013","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}